MapLight Therapeutics annual return on equity
2025
MapLight Therapeutics Return on Equity (ROE) Growth & History (MPLT)
MapLight Therapeutics's return on equity was −121.74% for fiscal 2025.
View full MapLight Therapeutics company overviewMapLight Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −121.74% | — |
MapLight Therapeutics quarterly return on equity
Q2.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −16.09% | +21.99 pp |
| Q1 2026 | 2026-03-31 | −14.14% | — |
| Q4 2025 | 2025-12-31 | −86.37% | — |
| Q2 2025 | 2025-06-30 | −38.08% | — |
MapLight Therapeutics return on equity trends
The latest reported quarter, Q2 2026, shows −16.09%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review MapLight Therapeutics source filings ↗